Comment re: Continuous rather than intermittent administration of fenretinide in leukoplakia

Cancer Prevention Research

Volumn 2, Issue 3, 2009, Pages 281-

  Formelli, Franca ^a   Cavadini, Elena ^a   Appierto, Valentina ^a   Tiberio, Paolo ^a   Grigolato, Roberto ^b   Chiesa, Fausto ^b   Tradati, Nicoletta ^b   Persiani, Stefano ^c  

^a Istituto Nazionale dei Tumori   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Rottapharm Madaus ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IN VITRO STUDY; LETTER; LEUKOPLAKIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RELAPSE; STEADY STATE;

ANTICARCINOGENIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FENRETINIDE; HUMANS; LEUKOPLAKIA, ORAL; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 68349096174     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0011     Document Type: Letter

References (4)

1. William WN, Jr., Lee JJ, Lippman SM, et al. High-dose fenretinide in oral leukoplakia. Cancer Prev Res 2009;2:22-26
2. Lippman SM, Lee JJ, Martin JW, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 2006;12:3109-3114
3. Chiesa F, Tradati N, Marazza M, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Oral Oncol Eur J Cancer 1992;28B:97-102.
4. Chiesa F, Tradati N, Grigolato R, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005;115:625-629 (Pubitemid 40656722)